Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia

• Status: Completed
• Trial end date: 2006-02-28
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if Sarizotan HC1 1 mg b.i.d. (taken twice a day) is effective in the treatment of dyskinesia associated with dopaminergic treatment of Parkinson's disease (PD).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: EMD Serono

Criteria

Inclusion Criteria:

• The subject is an out-patient.

• The subject presents with a diagnosis of idiopathic Parkinson's disease.

• Prior therapy with all registered Parkinsonian medication is allowed.

Exclusion Criteria:

• (For female subjects) The subject is pregnant or lactating.

• The subject is participating in another clinical study or has done so within the past 30 days.

• The subject has received neurosurgical intervention related to PD.

• The subject has relevant renal impairment.

• The subject has relevant hepatic impairment.

• The subject is suffering from any dementia or psychiatric illness.

• The subject has a history of allergic asthma.